Teva Pharmaceutical Industries Price to Free Cash Flow Ratio 2010-2024 | TEVA
Historical price to free cash flow ratio values for Teva Pharmaceutical Industries (TEVA) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Teva Pharmaceutical Industries Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-12-20 |
22.09 |
|
17.65 |
| 2024-09-30 |
18.02 |
$1.25 |
14.40 |
| 2024-06-30 |
16.25 |
$0.62 |
26.24 |
| 2024-03-31 |
14.11 |
$0.85 |
16.69 |
| 2023-12-31 |
10.44 |
$0.81 |
12.84 |
| 2023-09-30 |
10.20 |
$0.63 |
16.07 |
| 2023-06-30 |
7.53 |
$1.13 |
6.65 |
| 2023-03-31 |
8.85 |
$0.91 |
9.72 |
| 2022-12-31 |
9.12 |
$1.00 |
9.12 |
| 2022-09-30 |
8.07 |
$0.54 |
14.92 |
| 2022-06-30 |
7.52 |
$0.52 |
14.45 |
| 2022-03-31 |
9.39 |
$0.71 |
13.28 |
| 2021-12-31 |
8.01 |
$0.49 |
16.21 |
| 2021-09-30 |
9.74 |
$0.34 |
29.00 |
| 2021-06-30 |
9.90 |
$0.14 |
72.69 |
| 2021-03-31 |
11.54 |
$0.10 |
115.28 |
| 2020-12-31 |
9.65 |
$0.64 |
14.99 |
| 2020-09-30 |
9.01 |
$1.04 |
8.70 |
| 2020-06-30 |
12.33 |
$1.05 |
11.75 |
| 2020-03-31 |
8.98 |
$0.69 |
13.06 |
| 2019-12-31 |
9.80 |
$0.52 |
18.89 |
| 2019-09-30 |
6.88 |
$0.99 |
6.94 |
| 2019-06-30 |
9.23 |
$0.27 |
34.30 |
| 2019-03-31 |
15.68 |
$0.51 |
30.55 |
| 2018-12-31 |
15.42 |
$2.63 |
5.86 |
| 2018-09-30 |
21.54 |
$4.04 |
5.33 |
| 2018-06-30 |
24.32 |
$5.28 |
4.61 |
| 2018-03-31 |
17.09 |
$5.54 |
3.08 |
| 2017-12-31 |
18.95 |
$4.75 |
3.99 |
| 2017-09-30 |
17.50 |
$3.80 |
4.61 |
| 2017-06-30 |
32.86 |
$6.01 |
5.47 |
| 2017-03-31 |
31.37 |
$6.60 |
4.76 |
| 2016-12-31 |
35.10 |
$6.58 |
5.33 |
| 2016-09-30 |
44.14 |
$6.70 |
6.58 |
| 2016-06-30 |
47.88 |
$4.94 |
9.69 |
| 2016-03-31 |
50.67 |
$5.98 |
8.47 |
| 2015-12-31 |
61.79 |
$6.13 |
10.08 |
| 2015-09-30 |
52.84 |
$6.29 |
8.41 |
| 2015-06-30 |
55.04 |
$6.56 |
8.39 |
| 2015-03-31 |
57.70 |
$5.77 |
10.01 |
| 2014-12-31 |
52.94 |
$5.12 |
10.34 |
| 2014-09-30 |
49.21 |
$3.97 |
12.40 |
| 2014-06-30 |
47.68 |
$2.84 |
16.78 |
| 2014-03-31 |
47.72 |
$2.48 |
19.24 |
| 2013-12-31 |
35.94 |
$2.82 |
12.77 |
| 2013-09-30 |
33.63 |
$3.71 |
9.06 |
| 2013-06-30 |
34.66 |
$4.43 |
7.83 |
| 2013-03-31 |
34.85 |
$4.73 |
7.37 |
| 2012-12-31 |
32.57 |
$4.27 |
7.62 |
| 2012-09-30 |
35.94 |
$4.14 |
8.69 |
| 2012-06-30 |
34.05 |
$3.41 |
9.97 |
| 2012-03-31 |
38.70 |
$3.62 |
10.69 |
| 2011-12-31 |
34.51 |
$3.76 |
9.17 |
| 2011-09-30 |
31.69 |
$2.64 |
12.02 |
| 2011-06-30 |
40.86 |
$3.54 |
11.54 |
| 2011-03-31 |
42.35 |
$3.70 |
11.46 |
| 2010-12-31 |
43.81 |
$3.72 |
11.78 |
| 2010-09-30 |
44.18 |
$4.36 |
10.14 |
| 2010-06-30 |
43.40 |
$4.05 |
10.72 |
| 2010-03-31 |
52.51 |
$3.16 |
16.59 |
| 2009-12-31 |
46.64 |
$2.95 |
15.82 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$24.142B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
